

Study or Subgroup	Cilostazol Events	Cilostazol Total	Control Events	Control Total	Peto Odds Ratio Peto, Fixed, 95% CI	Year
7.2.1 Acute/subacute Cil v no Cil						
Subtotal (95% CI)		**0**		**0**	**Not estimable**	
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
7.2.2 Acute/subacute Cil+Asp or Clop v Asp or Clop						
TOSS	0	67	0	68	Not estimable	2005
Nakamura	2	38	3	38	0.66 [0.11, 3.97]	2012
ECLIPse	1	100	1	103	1.03 [0.06, 16.59]	2013
Shimizu (1)	3	251	4	256	0.76 [0.17, 3.39]	2013
Ohnuki	0	13	0	11	Not estimable	2017
Subtotal (95% CI)		**469**		**476**	**0.76 [0.26, 2.19]**	
Total events	6		8			
Heterogeneity: Chi² = 0.07, df = 2 (P = 0.96); I² = 0%						
Test for overall effect: Z = 0.51 (P = 0.61)						
7.2.3 Acute/subacute Cil v Asp or Clop						
CAIST	4	231	5	227	0.78 [0.21, 2.93]	2011
Lee (2)	1	40	0	40	7.39 [0.15, 372.38]	2017
Subtotal (95% CI)		**271**		**267**	**0.98 [0.28, 3.43]**	
Total events	5		5			
Heterogeneity: Chi² = 1.13, df = 1 (P = 0.29); I² = 12%						
Test for overall effect: Z = 0.03 (P = 0.98)						
7.2.4 Acute/subacute Cil+Asp v Clop+Asp						
TOSS-2	10	232	6	225	1.62 [0.60, 4.40]	2011
Subtotal (95% CI)		**232**		**225**	**1.62 [0.60, 4.40]**	
Total events	10		6			
Heterogeneity: Not applicable						
Test for overall effect: Z = 0.95 (P = 0.34)						
7.2.5 Chronic Cil v no Cil						
CSPS	30	533	57	534	0.51 [0.33, 0.79]	2000
Subtotal (95% CI)		**533**		**534**	**0.51 [0.33, 0.79]**	
Total events	30		57			
Heterogeneity: Not applicable						
Test for overall effect: Z = 3.01 (P = 0.003)						
7.2.6 Chronic Cil+Asp or Clop v Asp or Clop						
CATHARSIS	4	83	6	80	0.63 [0.18, 2.25]	2015
LACI-1 (3)	1	42	0	15	3.89 [0.05, 332.98]	2019
CSPS.com (4)	29	932	64	947	0.46 [0.30, 0.70]	2019
Subtotal (95% CI)		**1057**		**1042**	**0.48 [0.33, 0.72]**	
Total events	34		70			
Heterogeneity: Chi² = 1.06, df = 2 (P = 0.59); I² = 0%						
Test for overall effect: Z = 3.62 (P = 0.0003)						
7.2.7 Chronic Cil v Asp or Clop						
CASISP	11	360	15	359	0.72 [0.33, 1.59]	2008
Guo	2	34	1	34	1.99 [0.20, 19.78]	2009
CSPS 2	72	1337	88	1335	0.81 [0.59, 1.11]	2010
Johkura	0	57	0	49	Not estimable	2012
PICASSO	40	766	55	768	0.72 [0.47, 1.08]	2018
Subtotal (95% CI)		**2554**		**2545**	**0.78 [0.61, 0.99]**	
Total events	125		159			
Heterogeneity: Chi² = 0.87, df = 3 (P = 0.83); I² = 0%						
Test for overall effect: Z = 2.08 (P = 0.04)						
7.2.8 Chronic Cil+Asp v Clop+Asp						
Sakurai (5)	0	11	0	9	Not estimable	2013
Subtotal (95% CI)		**11**		**9**	**Not estimable**	
Total events	0		0			
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
Total (95% CI)		**5127**		**5098**	**0.68 [0.57, 0.81]**	
Total events	210		305			
Heterogeneity: Chi² = 12.14, df = 13 (P = 0.52); I² = 0%						
Test for overall effect: Z = 4.32 (P < 0.0001)						
Test for subgroup differences: Chi² = 9.00, df = 5 (P = 0.11), I² = 44.5%						

Footnotes

(1) Comparison group received placebo OR no treatment.
(2) Comparison group received aspirin OR placebo.
(3) Comparison group received aspirin OR Clopidogrel.
(4) Comparison group treated with aspirin OR Clopidogrel.
(5) Comparison group received aspirin AND Clopidogrel.